Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.19
Views: 1212

Prof Brian Rini - Cleveland Clinic, Cleveland, USA

Prof Brian Rini speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about the Tivo-3 study.

He immediately outlines the benefits of tivozanib's toxicity profile compared to other tyrosine kinase inhibitors (TKIs).

Prof Rini then outlines the design and findings of the Tivo-3 trial, and the extraordinary durability of response with tivozanib.

Finally he outlines the next step which is to round off the study with the survival analysis that will be concluded later this year.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation